EFFICACY AND TOLERABILITY OF A SINGLE-DAY THREE DRUG COMBINATION OF APREPITANT, PALONOSETRON AND DEXAMETHASONE IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY

被引：0
|
作者：
Quadrini, S. [1 ]
Longo, F. [1 ]
Lapadula, V [1 ]
Stumbo, L. [1 ]
De Sanctis, R. [1 ]
D'Antoni, I [1 ]
Del Signore, E. [1 ]
Gori, B. [1 ]
Viggiani, E. [1 ]
Vairano, M. [1 ]
Di Seri, M. [1 ]
机构：
[1] Policlin Umberto 1, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [32] Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy
    Takeshi Ioroi
    Junya Furukawa
    Manabu Kume
    Sachi Hirata
    Yuko Utsubo
    Naomi Mizuta
    Hideaki Miyake
    Masato Fujisawa
    Midori Hirai
    Supportive Care in Cancer, 2018, 26 : 1419 - 1423
  • [33] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Winnie Yeo
    F. K. F. Mo
    J. J. S. Suen
    W. M. Ho
    S. L. Chan
    W. Lau
    J. Koh
    W. K. Yeung
    W. H. Kwan
    K. K. C. Lee
    T. S. K. Mok
    A. N. Y. Poon
    K. C. Lam
    E. K. Hui
    B. Zee
    Breast Cancer Research and Treatment, 2009, 113 : 529 - 535
  • [34] Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy
    Ioroi, Takeshi
    Furukawa, Junya
    Kume, Manabu
    Hirata, Sachi
    Utsubo, Yuko
    Mizuta, Naomi
    Miyake, Hideaki
    Fujisawa, Masato
    Hirai, Midori
    SUPPORTIVE CARE IN CANCER, 2018, 26 (05) : 1419 - 1423
  • [35] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
    Herrstedt, J
    Muss, HB
    Warr, DG
    Hesketh, PJ
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    CANCER, 2005, 104 (07) : 1548 - 1555
  • [36] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, Winnie
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Lau, W.
    Koh, J.
    Yeung, W. K.
    Kwan, W. H.
    Lee, K. K. C.
    Mok, T. S. K.
    Poon, A. N. Y.
    Lam, K. C.
    Hui, E. K.
    Zee, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 529 - 535
  • [37] Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
    Kang, Jin Hyoung
    Kwon, Jung Hye
    Lee, Yun-Gyoo
    Park, Keon Uk
    An, Ho Jung
    Sohn, Joohyuk
    Seol, Young Mi
    Lee, Hyunwoo
    Yun, Hwan-Jung
    Ahn, Jin Seok
    Yang, Ji Hyun
    Song, Hunho
    Koo, Dong-Hoe
    Kim, Jin Young
    Kim, Gun Min
    Kim, Hwa Jung
    CANCER RESEARCH AND TREATMENT, 2020, 52 (03): : 907 - 916
  • [38] Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy.
    Sra, Manraj Singh
    Rasheed, Azgar Abdul
    Ganguly, Shuvadeep
    Kumar, Santosh
    Sharma, Priya
    Pillai, Ashwati S.
    Sharma, Swetambri
    Pushpam, Deepam
    Bakhshi, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    Aapro, M.
    Fabi, A.
    Nole, F.
    Medici, M.
    Steger, G.
    Bachmann, C.
    Roncoroni, S.
    Roila, F.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1083 - 1088
  • [40] Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
    Gao, H. F.
    Liang, Y.
    Zhou, N. N.
    Zhang, D. S.
    Wu, H. Y.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 73 - 76
12345